Overview

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Henlius Biotech